anti-ox40
mAbexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT01644968)
Timeline
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-ox40
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02274155 | Phase 1 | Oct 1, 2014 | MedImmune, Providence Health & Services |
| NCT01689870 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | AgonOx, Cornell University, Ludwig Institute for Cancer Research, Providence Health & Services |
| NCT01416844 | Phase 2 | Sep 1, 2012 | Providence Health & Services |
| NCT01303705 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | MedImmune, Providence Health & Services |
| NCT01644968 | Phase 1 | Nov 1, 2003 | Providence Health & Services |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Providence Health & Services | Academic/Hospital | 5 | 4 | 2 | 2003 |
| MedImmune | For profit | 2 | 0 | 2 | 2010 |
| AgonOx | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2014 |
5 organizations
Page 1 / 1